New drug shows promise in metastatic prostate cancer

Reuters Health - 25/09/2020 - The experimental oral tubulin inhibitor VERU-111 has shown antitumor activity in men with metastatic castration-resistant prostate cancer (mCRPC) and has a favorable safety profile allowing for continuous administration, according to new research. In the phase 1b/2 study, VERU-111 was associated with reductions in prostate-specific antigen (PSA), objective tumor responses and durable activity in men with previously treated mCRPC, Dr. Mark Markowski of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, reported at the virtual 2020 meeting of the European Society for Medical Oncology (ESMO). The phase 1b portion of the study enrolled 39 men (median age, 74) with mCRPC at seven centers in the United States; both abiraterone and enzalutamide had failed in 44% of these men; 55% had bone-only metastatic disease and nine (23%) had previously received taxane. This safety and dose-finding study used a two-...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 September, 202029 September, 2020